Johnson & Johnson (NYSE:JNJ) Holdings Decreased by Norwood Financial Corp

Norwood Financial Corp reduced its stake in shares of Johnson & Johnson (NYSE:JNJFree Report) by 5.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,294 shares of the company’s stock after selling 388 shares during the quarter. Johnson & Johnson comprises approximately 1.5% of Norwood Financial Corp’s holdings, making the stock its 12th largest position. Norwood Financial Corp’s holdings in Johnson & Johnson were worth $987,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. RPG Investment Advisory LLC lifted its holdings in Johnson & Johnson by 1.2% during the 2nd quarter. RPG Investment Advisory LLC now owns 4,876 shares of the company’s stock worth $807,000 after purchasing an additional 60 shares in the last quarter. FIDELIS iM LLC raised its holdings in shares of Johnson & Johnson by 3.1% in the 4th quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock valued at $374,000 after acquiring an additional 64 shares in the last quarter. TFG Advisers LLC increased its position in shares of Johnson & Johnson by 0.4% during the 3rd quarter. TFG Advisers LLC now owns 18,330 shares of the company’s stock valued at $2,855,000 after purchasing an additional 67 shares during the last quarter. Kellett Wealth Advisors LLC increased its position in shares of Johnson & Johnson by 3.8% during the 3rd quarter. Kellett Wealth Advisors LLC now owns 1,880 shares of the company’s stock valued at $293,000 after purchasing an additional 68 shares during the last quarter. Finally, Hutchinson Capital Management CA grew its position in Johnson & Johnson by 0.6% during the 3rd quarter. Hutchinson Capital Management CA now owns 10,566 shares of the company’s stock worth $1,646,000 after acquiring an additional 68 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Wells Fargo & Company lowered Johnson & Johnson from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $170.00 to $163.00 in a research report on Wednesday, December 13th. Raymond James raised their target price on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, January 3rd. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, Morgan Stanley lowered their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 24th. Seven equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $177.31.

Read Our Latest Stock Report on JNJ

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the completion of the transaction, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total value of $96,142.25. Following the completion of the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares of the company’s stock, valued at $22,099,078.32. The disclosure for this sale can be found here. 0.20% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $155.21 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97. The stock has a 50-day moving average price of $159.14 and a 200 day moving average price of $156.83. The stock has a market capitalization of $374.02 billion, a P/E ratio of 11.24, a P/E/G ratio of 2.62 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 37.27% and a net margin of 37.79%. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter last year, the business posted $2.35 earnings per share. The firm’s revenue was down 9.7% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th were paid a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date of this dividend was Friday, February 16th. Johnson & Johnson’s payout ratio is presently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.